Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Rudolf Valenta is active.

Publication


Featured researches published by Rudolf Valenta.


Archive | 1996

Profilin: A Novel Pan-Allergen and Actin-Binding Protein in Plants

Rudolf Valenta; Ines Swoboda; Monika Grote; Susanne Vrtala; Fatima Ferreira; Michael Duchêne; Erwin Heberle-Bors; Dietrich Kraft; Otto Scheiner

Using serum-IgE from a pollen-allergic patient we isolated a cDNA from a birch pollen expression library (Valenta et al., 1991a). The deduced amino acid sequence of this cDNA clone showed significant homology with sequences from other eukaryotic profilins. Profilins function as actin-binding proteins (Isenberg et al., 1980) and interact with phosphatidylinositol 4,5 bisphosphate (PIP2) (Goldschmidt-Clermont et al., 1990). In addition a role of profilins in the signal transduction cascade via CAP was proposed (Vojtek et al., 1991). These data indicate that profilins are essential components of eukaryotic cells. This chapter concerning the biological functions of plant profilins illustrates that these proteins are ubiquitously distributed in plants and are structurally similar. For this reason plant profilins can function as targets for cross-reactive IgE antibodies of allergic patients and represent a novel class of pan-allergens.


International Archives of Allergy and Immunology | 1999

Expression of a Human IgG4 Antibody, BAB2, with Specificity for the Major Birch Pollen Allergen, Bet v 1 in Escherichia coli: Recombinant BAB2 Fabs Enhance the Allergic Reaction

Petra Eibensteiner; Stéphane Denépoux; Peter Steinberger; Dietrich Kraft; Vincenzo Visco; Jacques Banchereau; Serge Lebecque; Rudolf Valenta

Background: Antigen recognition by antibodies of different isotypes can result in completely different effects as exemplified by Type I allergy. While the IgE–antibody–mediated release of biological mediators constitutes the immunopathological basis for the immediate symptoms observed in allergic patients, allergen–specific IgG antibodies are thought to have protective effects. Methods: Cell lines secreting five human monoclonal IgG antibodies (BAB1–BAB5) with specificity for the major birch pollen allergen Bet v 1 were established from a birch–pollen–allergic patient who had received birch– pollen–specific immunotherapy. The influence of the Bet v 1–specific IgG antibodies on IgE binding to Bet v 1 was investigated. BAB2 was expressed in Escherichia coli as recombinant Fab, purified and tested for its ability to modulate Bet v 1–induced immediate–type skin reactions. Results: The BAB antibodies belonged to different IgG subclasses (BAB1: IgG1; BAB2, BAB3, BAB5: IgG4; and BAB4: IgG2) reflecting a tendency towards Th2. BAB1 represented the only antibody which strongly blocked IgE binding to Bet v 1, whereas BAB 3–BAB5 had little effect on IgE binding. Surprisingly, natural BAB2 antibodies as well as recombinant BAB2 Fabs strongly enhanced IgE binding to Bet v 1 and Bet v 1–induced immediate–type skin reactions and thus represent ‘enhancing antibodies’. Conclusion: The demonstration that anti–allergen IgG antibodies can also enhance IgE binding to a given allergen explains the unpredictability of specific immunotherapy as well as the controversy on the role of IgG in atopy.


Archive | 2017

VVX001: A promising novel hepatitis B vaccine candidate

Rainer Henning; Carolin Cornelius Katrin Schneweis Stephan Urban; Rudolf Valenta

C trachomatis is a bacterial agent that causes sexually transmitted infections worldwide. The regulatory functions of dendritic cells (DCs) play a major role in protective immunity against chlamydia infections. The mechanisms underlying this immunomodulation are not fully understood. The inflammasome adaptor protein, apoptosis-associated speck-like protein containing a CARD (ASC) regulates the direction of immunity against such bacterial infections. Here, we investigate whether ASC, the critical components of inflammasome activation, participate in regulation of DC activation and function and the possible mechanisms during chlamydia infection. We observed that following chlamydia stimulation, the maturation and antigen presenting task of ASC-/DCs were impaired compare to wild type DC (WT DC). Also, ASC deficiency induces a tolerogenic phenotype in chlamydia stimulated DCs, which may induce immune pathological response in infected host. We observed that following chlamydia stimulation of ASC/DCs prevented the chlamydia-induced increase in aerobic glycolysis, measured as extracellular acidification rates (ECARs) and had significantly reduced pyruvate production from the metabolism of glucose during glycolysis. To determine the effect of this reduction in pyruvate production in cellular respiration, we determined the morphology of the mitochondria. The results revealed that the mitochondria of infected ASC-/-DCs had their cristae disrupted compared to the normal narrow pleomorphic cristae found in un-stimulated WT, ASC-/and stimulated WT DCs. In conclusion, the results suggest that ASC deficiency interrupts DC function through reprogramming of DC metabolism starting from glycolysis to the electron transport chain which occurs within the mitochondria, which controls the actions and functions of DCs during chlamydia infection. The interface between ACS and metabolism in innate immunity is of great interest. It may be possible for small molecules to reprogram the metabolism of immune cells to enhance vaccine efficacy against infectious diseases and tumors.


Archive | 1991

Birch pollen allergen p14 for diagnosis and therapy of allergic diseases

Rudolf Valenta; Michael Duchêne; Karin Pettenburger; Michael Breitenbach; Dietrich Kraft; Helmut Rumpold; Otto Scheiner


Archive | 1995

Recombinant allergen, fragments thereof, corresponding recombinant dna molecules, vectors and hosts containing the dna molecules, diagnostic and therapeutic uses of said allergens and fragments

Tanja Ball; Susanne Vrtala; Wolfgang R. Sperr; Peter Valent; Markus Susani; Dietrich Kraft; Rudolf Valenta; Sylvia Laffer


Archive | 2003

Process for the preparation of hypoallergenic mosaic proteins

Nadine Mothes; Sabine Stumvoll; M. Focke; Birgit Linhart; Maria-Theresa Krauth; Peter Valent; Dietrich Kraft; Rudolf Valenta


Archive | 1991

Allergens of alder pollen and applications thereof

Heimo Breiteneder; Rudolf Valenta; Michael Breitenbach; Dietrich Kraft; Helmut Rumpold; Otto Scheiner


Archive | 1998

Non-anaphylactic forms of allergens and their use

Rudolf Valenta; Susanne Vrtala; Luca Vangelista; Hans-Georg Eichler; Wolfgang R. Sperr; Peter Valent; Christof Ebner; Dietrich Kraft; Hans Grönlund


Archive | 1995

Method of production of birch pollen allergen P14

Rudolf Valenta; Michael Duchêne; Karin Pettenburger; Michael Breitenbach; Dietrich Kraft; Helmut Rumpold; Otto Scheiner


Archive | 1995

Recombinant allergen, fragments thereof, corresponding recombinant DNA molecules, vectors and hosts containing the DNA molecules

Tanja Ball; Susanne Vrtala; Wolfgang R. Sperr; Peter Valent; Markus Susani; Dietrich Kraft; Rudolf Valenta; Sylvia Laffer

Collaboration


Dive into the Rudolf Valenta's collaboration.

Top Co-Authors

Avatar

Dietrich Kraft

Medical University of Vienna

View shared research outputs
Top Co-Authors

Avatar

Peter Valent

Vienna General Hospital

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Wolfgang R. Sperr

Medical University of Vienna

View shared research outputs
Top Co-Authors

Avatar

Otto Scheiner

Medical University of Vienna

View shared research outputs
Top Co-Authors

Avatar

Susanne Spitzauer

Medical University of Vienna

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge